Journal Watch · eLife · 2026

Adapting clinical chemistry plasma as a source for liquid biopsies.

These findings support the feasibility of using refrigerated, promptly processed residual plasma from routine clinical chemistry as a supplementary source for cfDNA biobanking and molecular analyses.

Ding SC, Yu J, Liao T et al.eLife3 min readPharma relevance 65/100

DOI: 10.7554/elife.108708PMID: 42065375Study type: cohort / observational clinical study

TL;DR

These findings support the feasibility of using refrigerated, promptly processed residual plasma from routine clinical chemistry as a supplementary source for cfDNA biobanking and molecular analyses.

Key findings

  • In the Hospital Cohort, heparin separator plasma showed strong concordance with matched EDTA plasma for viral detection (Spearman's ρ=0.95), copy number alteration profiling (Spearman's ρ=0.72-0.96), and methylation patterns (Spearman's ρ=0.50-0.83).
  • These findings support the feasibility of using refrigerated, promptly processed residual plasma from routine clinical chemistry as a supplementary source for cfDNA biobanking and molecular analyses.

Numbers at a glance (from the abstract)

n=5n=6n=38or 4

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

We also analyzed matched plasma samples from viral PCR-positive patients in a hospital cohort (n=38). Whole-genome sequencing and enriched methylation sequencing were performed to assess concordance across metagenomics, copy number, methylation, and fragmentomic features. Under immediate processing, heparin separator plasma showed high concordance with EDTA and Streck plasma for methylation patterns (Spearman's ρ=0.65-0.70) and fragmentation features.

Full abstract (original)

Background: Circulating cell-free DNA (cfDNA) is valuable for molecular testing, but typically requires specialized collection tubes or immediate processing. We investigated whether residual plasma from heparin separators, routinely used in clinical chemistry, could serve as an accessible and underused source for cfDNA. We analyzed matched plasma samples from healthy volunteers in two experiments: an immediate-processing comparison across EDTA, Streck, and heparin separator tubes (n=5), and a clinical-handling simulation comparing EDTA and heparin separator tubes under delayed processing at room temperature or 4°C (n=6).

What they did: We also analyzed matched plasma samples from viral PCR-positive patients in a hospital cohort (n=38). Whole-genome sequencing and enriched methylation sequencing were performed to assess concordance across metagenomics, copy number, methylation, and fragmentomic features. Under immediate processing, heparin separator plasma showed high concordance with EDTA and Streck plasma for methylation patterns (Spearman's ρ=0.65-0.70) and fragmentation features.

Results & conclusions: In the Hospital Cohort, heparin separator plasma showed strong concordance with matched EDTA plasma for viral detection (Spearman's ρ=0.95), copy number alteration profiling (Spearman's ρ=0.72-0.96), and methylation patterns (Spearman's ρ=0.50-0.83). These findings support the feasibility of using refrigerated, promptly processed residual plasma from routine clinical chemistry as a supplementary source for cfDNA biobanking and molecular analyses.

Abstract © the authors / eLife (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.7554/elife.108708 · PubMed 42065375.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking eLife for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this eLife study find?

These findings support the feasibility of using refrigerated, promptly processed residual plasma from routine clinical chemistry as a supplementary source for cfDNA biobanking and molecular analyses.

What type of study is this?

It is a cohort / observational clinical study, published in eLife in 2026. We also analyzed matched plasma samples from viral PCR-positive patients in a hospital cohort (n=38).

Where can I read the original paper?

The original is at the publisher via DOI 10.7554/elife.108708. PubMed ID: 42065375. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ding SC, Yu J, Liao T et al.. Adapting clinical chemistry plasma as a source for liquid biopsies.. eLife (2026). DOI: 10.7554/elife.108708.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/adapting-clinical-chemistry-plasma-as-a-source-for-liquid-biopsies-108708/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides